Veradermics, Incorporated (MANE) stock analysis
In our weekly check, Veradermics, Incorporated is graded D (A to F). Of 15 checks on debt, profit, cash flow and trend: 5 pass, warnings: 3, red flags: 7.
About Veradermics, Incorporated
Veradermics, Incorporated is a Healthcare company (Biotechnology) based in the United States, listed on NYSE as MANE.
What our checks show for MANE
Red flags
- The company has an operating loss, so it does not cover the interest bill: interest is paid from cash or new debt.
- Weak EPS forecast
- The company has no revenue yet.
- Free cash flow is negative and the company has no revenue yet: it lives on its cash and new funding.
- The price swings a lot: 83.6% annual volatility. Expect large ups and downs.
- Return on capital (ROCE) is zero or negative: the business does not earn on the money put into it.
- Free cash flow is negative, so no cash is left over to cover pay in shares.
Warning signs
- Operating cash flow is negative while the company reports a profit: the profit does not arrive as cash.
- Analysts expect the net margin to shrink by 0.7 points from today's 0%.
- Beta 1.23: the stock usually moves more than the market, both up and down.
Strengths
- Debt is low: 0x equity.
- The share count fell by 99.6% in 2 years: the company buys back its own shares.
Similar companies
ERAS · PTCT · SRRK · DNTH · COGT · EWTX
Questions
What grade does Veradermics, Incorporated (MANE) have?
In our weekly check, Veradermics, Incorporated is graded D (A to F). Of 15 checks on debt, profit, cash flow and trend: 5 pass, warnings: 3, red flags: 7. The grade is a risk check, not a buy or sell recommendation.
What are the main risks of MANE stock?
This week's biggest flags for Veradermics, Incorporated: Weak interest cover, Weak EPS forecast, Thin margins. In total 10 of 15 checks show a warning or a red flag.
What does Veradermics, Incorporated do?
Veradermics, Incorporated is a Healthcare company (Biotechnology) based in the United States, listed on NYSE as MANE.
The grade is a risk check, not a price forecast, and not investment advice. In our 10-year test (S&P 500, 2016-2026), stocks we graded A or B fell more than 30% 2-3 times less often than D or F, without a lower average return.
Updated 2026-11-14
Open the full analysis